Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Octreotide 2telotristat ethyl 1isatuximab 1ceterizine hydrochloride 1capivasertib 1cabazitaxel 1XRP6258 1Prednisone 1Loperamide 1Leucovorin 1Lapatinib 1Irinotecan 1Injections 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Fluorouracil 1Filgrastim 1Drugs, Investigational 1Cyclophosphamide 1Colesevelam Hydrochloride 1Cell- and Tissue-Based Therapy 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Diarrhea × Calcium Aluminosilicate × Clear all
NCT00748215 2020-12-02

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 17 charts
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡